iOrganBio Appoints Karol Jarzabek as Chief Operating Officer

Adds Private Equity and Operational Experience to Help Scale iOrganBio's Operations

Jan. 28, 2026 at 8:31am

Got story updates? Submit your updates here. ›

iOrganBio, an innovator in intelligent cell manufacturing, has appointed Karol Jarzabek as its new Chief Operating Officer. Jarzabek brings extensive experience in operational management and business transformation, which will be crucial as iOrganBio scales its CellForge platform for reliable human cell production.

Why it matters

iOrganBio's CellForge platform aims to address long-standing challenges in human cell manufacturing, enabling more predictable, reproducible, and scalable production of cells for disease modeling, drug development, and cell therapy workflows. Jarzabek's leadership will be essential in supporting more partners and expanding the impact of this technology.

The details

As COO, Jarzabek will be responsible for coordinating cross-functional teams, overseeing operational execution, manufacturing scale-up, and regulatory alignment as iOrganBio continues to grow. He has a proven track record of driving strategic value and operational excellence across complex environments, including the biopharmaceutical sector.

  • iOrganBio recently emerged from stealth and introduced CellForge, its AI-powered platform for human cell manufacturing.
  • Jarzabek most recently served as Vice President of Portfolio Operations at QHP Capital, where he led value creation initiatives across 13 life science and pharmaceutical services companies.

The players

Karol Jarzabek

A seasoned operations leader with deep expertise in driving strategic value and operational excellence across complex environments, including the biopharmaceutical sector.

Daniel Delubac

The co-founder and CEO of iOrganBio, a company advancing its infrastructure to enable predictable, reproducible and scalable manufacturing of human cells.

iOrganBio

An innovator in intelligent cell manufacturing redefining how human cells are engineered and reliably produced at scale for research and therapy, including as New Approach Methodologies (NAMs) in alignment with FDA direction.

CellForge

An AI-powered platform built by iOrganBio to address long-standing challenges in human cell manufacturing, integrating data, automation, and experimental control to enable reliable human cell production.

QHP Capital

A private equity firm where Jarzabek previously served as Vice President of Portfolio Operations, leading value creation initiatives across 13 life science and pharmaceutical services companies.

Got photos? Submit your photos here. ›

What they’re saying

“We are advancing our infrastructure to enable predictable, reproducible and scalable manufacturing of human cells.”

— Daniel Delubac, co-founder and CEO of iOrganBio

“What impressed me about iOrganBio is how intentionally the platform was designed from the start. There is strong integration between the science and data infrastructure. The team is applying true engineering rigor to complex biological systems, creating a foundation that can actually scale. This approach has the potential to fundamentally change how therapies are developed for patients, and I am excited to help translate that vision into durable, scalable operations as the company grows.”

— Karol Jarzabek, Chief Operating Officer, iOrganBio

The takeaway

iOrganBio's appointment of Karol Jarzabek as COO highlights the company's commitment to scaling its innovative CellForge platform, which aims to transform human cell production and accelerate advancements in disease modeling, regenerative medicine, and drug development.